A new IFN-like cytokine, limitin, modulates the immune response without influencing thymocyte development. 2001

I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan.

A novel IFN-like molecule, limitin, was recently identified and revealed to suppress B lymphopoiesis through the IFN-alphabeta receptor, although it lacked growth suppression on myeloid and erythroid progenitors. Here we have studied diverse effects of limitin on T lymphocytes and compared limitin with previously known IFNs. Like IFN-alpha and -beta, limitin modified immunity in the following responses. It suppressed mitogen- and Ag-induced T cell proliferation through inhibiting the responsiveness to exogenous IL-2 rather than suppressing the production of IL-2. In contrast, limitin enhanced cytotoxic T lymphocyte activity associated with the perforin-granzyme pathway. To evaluate the effect of limitin in vivo, a lethal graft-versus-host disease assay was established. Limitin-treatment of host mice resulted in the enhancement of graft-versus-host disease. Limitin did not influence thymocyte development either in fetal thymus organ cultures or in newborn mice injected with limitin-Ig, suggesting that limitin is distinguishable from IFN-alpha and -beta. From these findings, it can be speculated that the human homolog of limitin may be applicable for clinical usage because of its IFN-like activities with low adverse effects on, for example, T lymphopoiesis, erythropoiesis, and myelopoiesis.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009924 Organ Culture Techniques A technique for maintenance or growth of animal organs in vitro. It refers to three-dimensional cultures of undisaggregated tissue retaining some or all of the histological features of the tissue in vivo. (Freshney, Culture of Animal Cells, 3d ed, p1) Organ Culture,Culture Technique, Organ,Culture Techniques, Organ,Organ Culture Technique,Organ Cultures
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D011828 Radiation Chimera An organism whose body contains cell populations of different genotypes as a result of the TRANSPLANTATION of donor cells after sufficient ionizing radiation to destroy the mature recipient's cells which would otherwise reject the donor cells. Chimera, Radiation,Chimeras, Radiation,Radiation Chimeras
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M

Related Publications

I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
May 2001, Journal of molecular medicine (Berlin, Germany),
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
June 2000, Nature medicine,
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
January 2005, Journal of cellular and molecular medicine,
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
May 2016, Brain, behavior, and immunity,
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
August 2003, Immunity,
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
July 2009, Journal of immunology (Baltimore, Md. : 1950),
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
July 2001, Proceedings of the National Academy of Sciences of the United States of America,
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
August 2005, Ugeskrift for laeger,
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
November 2021, Microbial pathogenesis,
I Takahashi, and H Kosaka, and K Oritani, and W R Heath, and J Ishikawa, and Y Okajima, and M Ogawa, and S Kawamoto, and M Yamada, and H Azukizawa, and S Itami, and K Yoshikawa, and Y Tomiyama, and Y Matsuzawa
September 2011, EMBO reports,
Copied contents to your clipboard!